Launch of Official Website for Treg Therapy for ALS Patients Marks a New Treatment Era
Introduction to Treg Therapy for ALS
On June 16, 2026, the Keishin Medical Corporation, based in Shinjuku, Tokyo, launched the official website for Treg therapy, also known as TALS therapy. This groundbreaking treatment focuses on regulatory T cells (Tregs) as a potential new option for patients suffering from Amyotrophic Lateral Sclerosis (ALS), a progressive and severe neurological disease that affects motor neurons and leads to a decline in muscle strength across the body.
The launch of this website aims to provide ALS patients and their families with comprehensive information about TALS therapy, presenting the latest medical evidence and treatment options in an accessible manner. With ALS being a complex condition characterized by inflammation of the brain and spinal cord, the site serves as a reliable resource to explore this innovative treatment approach.
Purpose and Background of the Website
Recent medical research has highlighted the significant role that neuroinflammation plays in the progression of ALS. By focusing on the function of Tregs, which act as a
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.